Skip to main content

Table 5 Factors associated with unsuccessful treatment outcomes among new pulmonary smear-negative tuberculosis patients in Anqing, China, 2005–2013 (n = 8156)

From: Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study

Variables Total (n = 8156) Unsuccessful outcomes Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Sex Female 2266 (27.78) 112 (4.94) 1    
Male 5890 (72.22) 296 (5.03) 1.02 (0.81, 1.27) 0.88   
Age 15~ 24 1237 (15.17) 36 (2.91) 1   1  
25~ 34 714 (8.75) 28 (3.92) 1.36 (0.82, 2.25) 0.23 1.34 (0.73, 2.47) 0.34
35~ 44 1189 (14.58) 43 (3.62) 1.25 (0.80, 1.96) 0.33 1.22(0.69, 2.16) 0.50
45~ 54 1275 (15.63) 65 (5.10) 1.79 (1.18, 2.71) < 0.001 1.79 (1.04, 3.09) 0.04
55~ 64 1744 (21.38) 87 (4.99) 1.75 (1.18, 2.60) < 0.001 1.59 (0.93, 2.74) 0.09
≥65 1997 (24.49) 149 (7.46) 2.69 (1.86, 3.90) < 0.001 2.57 (1.52, 4.35) < 0.001
Ethnicity Han 8141 (99.82) 407 (5.00) 0.74 (0.10, 5.62) 0.54   
Other 15 (0.18) 1 (6.67) 1    
Occupation Student 607 (7.44) 19 (3.13) 1    
Official staff 166 (2.04) 12 (7.23) 2.41 (1.15, 5.08) 0.02   
Service 160 (1.96) 6 (3.75) 1.21 (0.47, 3.07) 0.69   
Worker 683 (8.37) 28 (4.10) 1.32 (0.73, 2.39) 0.36   
Farmer 5940 (72.83) 321 (5.40) 1.77 (1.10, 2.83) 0.02   
Retired staff 172 (2.11) 13 (7.56) 2.53 (1.22, 5.23) 0.01   
Unemployment 140 (1.72) 4 (2.86) 0.91 (0.31, 2.72) 0.87   
Other 388 (3.53) 5 (1.74) 0.55 (0.20, 1.48) 0.23   
Way of discovering patients Health examination 165 (2.02) 5 (3.03) 1    
Contact examination 40 (0.49) 2 (5.00) 1.68 (0.32, 9.01) 0.54   
Clinic visit due to symptoms 3548 (43.50) 175 (4.93) 1.66 (0.67, 4.10) 0.27   
Recommended due to symptoms 30 (0.37) 1 (3.33) 1.10 (0.12, 9.79) 0.93   
Referral 3793 (46.51) 197 (5.19) 1.75 (0.71, 4.32) 0.22   
Tracing 559 (6.85) 27 (4.83) 1.62 (0.62, 4.29) 0.33   
Other 21 (0.26) 1 (4.76) 1.60 (0.18, 14.39) 0.68   
Treatment management models Self-medication 30 (0.37) 4 (13.33) 2.84 (0.96, 8.41) 0.06 2.95 (0.98, 8.90) 0.055
Full-course supervision 1049 (12.86) 54 (5.15) 1   1  
Full-course management 513 (6.29) 59(11.50) 2.40 (1.63, 3.52) < 0.001 2.54 (1.70, 3.81) < 0.001
Supervision in intensive phase 6564 (80.48) 291 (4.43) 0.86 (0.63, 1.15) 0.30 0.95 (0.70, 1.30) 0.76
X-Ray Normal 122 (1.50) 0 < 0.01 (< 0.01, > 999.99) 0.96
Abnormal 8000 (98.09) 402 (5.03) 1   1  
Unchecked 34 (0.42) 6 (17.65) 4.00(1.67–10.00) 0.002 3.77 (1.50, 9.45) 0.005
Cavity Yes 683 (8.37) 32 (4.69) 0.93 (0.64, 1.34) 0.69   
No 7473 (91.63) 376 (5.03) 1    
Miliary shadow Yes 70 (0.86) 8 (11.43) 2.48 (1.18, 5.21) 0.02 2.43 (1.12, 5.25) 0.02
No 8086 (99.14) 400 (4.95) 1   1  
Regimen Regimen 1a 5111 (62.67) 278 (5.44) 1    
Regimen 2b 3045 (37.33) 130 (4.27) 0.78 (0.63, 0.96) 0.02   
Total delay ≤13 2047 (25.10) 94 (4.59) 1   1  
13~ 27 2054 (25.18) 80 (3.89) 0.84 (0.62, 1.14) 0.27 0.84 (0.62, 1.14) 0.27
27~ 51 2046 (25.09) 100 (4.89) 1.07 (0.80, 1.43) 0.66 1.05(0.78, 1.41) 0.74
> 51 2009 (24.63) 134 (6.67) 1.49 (1.13, 1.95) 0.004 1.40 (1.06, 1.85) 0.019
  1. a2H3R3Z3E3/4H3R3. R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol. It means once once-every-other-day HRZE for 2 months followed by 4 months of once-every-other-day HR
  2. b2HRZE/4HR. It means daily HRZE for 2 months followed by 4 months of daily HR